The whole story: Treatment outcomes with Symbicort®

Respiratory Medicine

Volumn 96, Issue SUPPL. 1, 2002, Pages

  Zetterstrom O ^a,e   Buhl, R ^b   Mellem, H ^c   Andersson, F ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d ASTRAZENECA R AND D   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL; GLUCOCORTICOID; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE;

ASTHMA; AWARENESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DOCTOR PATIENT RELATION; DRUG COST; DRUG DOSE REGIMEN; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MEDICAL EDUCATION; MORTALITY; PATIENT COMPLIANCE; PATIENT EDUCATION; POWDER INHALER; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOCIOECONOMICS; WELLBEING; ADULT; AUSTRALIA; CANADA; CHILD; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; NEBULIZER; SWEDEN; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ASTHMA; AUSTRALIA; BRONCHODILATOR AGENTS; BUDESONIDE; CANADA; CHILD; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; ETHANOLAMINES; GREAT BRITAIN; HUMANS; NEBULIZERS AND VAPORIZERS; QUALITY OF LIFE; SWEDEN; TREATMENT OUTCOME; UNITED STATES;

EID: 10944233938     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(02)90080-6     Document Type: Review

References (57)

1. Upton MN, McConnachie A, McSharry C et al. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring. BMJ 2000; 321: 88-92.
2. Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol 2000; 106: 493-409.
3. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992; 326: 862-866.
4. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996; 9: 636-642.
5. British Guidelines on Asthma Management: 1995 review and position statement. Thorax 1997; 52 (Suppl 1): S1-S21.
6. National Institutes of Health: National Heart Lung and Blood Institute. National Asthma Education and Prevention Programme. Expert panel report II: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health (publication No. 97-4051); 1997
7. National Institutes of Health: National Heart Lung and Blood Institute. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report. Lenfant C, Khaltaev N. eds. Bethesda, MD: National Institutes of Health (publication No. 95-3659); 1995.
8. Dahl R, Bjermer L. Nordic consensus report on asthma management. Respir Med 2000; 94: 299-327
9. Mellis CM, Peat JK, Woolcock AJ. The cost of asthma: can it be reduced? Pharmacoeconomics 1993; 3: 205-219.
10. Lenney W. The burden of pediatric asthma. Pediatr Pulmonol Suppl 1997; 15: 13-16.
11. Jacobson L, Hertzman P, Löfdahl CG, Skoogh BE, Lindgren B. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med 2000; 94: 247-255.
12. Sullivan SD. Economics of asthma and asthma treatments. Eur Respir Rev 1998; 8: 351-355.
13. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12: 1322-1326.
14. Konig P, Johnson JC. Treatment of childhood asthma with anti-inflammatory drugs, according to guidelines, is cost-effective. Eur Respr J 1998; 12 (Suppl 28): 88s.
15. Neville RG, Pearson MG, Richards N et al. A cost analysis on the pattern of asthma prescribing in the UK. Eur Respir J 1999; 14: 605-609.
16. Roghmann MC, Sexton M. Adherence to asthma guidelines in general practices. J Asthma 1999; 36: 381-387
17. Lagerløv P, Veninga CCM, Muskova M et al. Asthma management in five European countries: doctors' knowledge, attitudes and prescribing behaviour. Drug Education Project (DEP) group Eur Respir J 2000; 15: 25-29.
18. Cerveri I, Locatelli F, Zoia MC, Corsico A, Accordini S, de Marco R. International variations in asthma treatment compliance: the results of the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1999; 14: 288-294.
19. Andersson F, Ståhl E, Barnes PJ et al. Adding formoterol to budesonide in moderate asthma-health economic results from the FACET study. Respir Med 2001; 95: 504-512.
20. Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B, Silverman S. Risk factors and costs associated with an asthma attack. Thorax 2000; 55: 19-24.
21. Boulet L-P. Asthma education: what has been its impact? Can Respir J 1998; 5 (Suppl A): 91A-96A.
22. Partridge MR, Hill SR, on behalf of the 1998 World Asthma Meeting Education and Delivery of Care Working Group. Enhancing care for people with asthma: the role of communication, education, training and self-management. Eur Respir J 2000; 16: 333-348.
23. Lagerløv P, Leseth A, Matheson I. The doctor-patient relationship and the management of asthma. Soc Sci Med 1998; 47: 85-91.
24. Lahdensuo A, Haahtela T, Herrala JP et al. Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland. BMJ 1998; 316: 1138-1139.
25. Bolton MB, Tilley BC, Kuder J, Reeves T, Schultz LR. The cost and effectiveness of an education program for adults who have asthma. J Gen Intern Med 1991; 6: 401-407
26. Haahtela T, Jarvinen M, Kava T et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700-705.
27. Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ, Kerrebijn KF. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992; 146: 547-554.
28. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157: S1-S53.
29. O'Byrne PM. Inhaled corticosteroid therapy in newly detected mild asthma. Drugs 1999; 58 (Suppl 4): 17-24.
30. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993; 148: S1-S26.
31. Nankani JN, Northfield M, Beran YM, Richardson PD. Changes in asthmatic patients' symptoms and lifestyles on institution of inhaled budesonide therapy. Curr Med Res Opin 1990; 12: 198-203.
32. Buston KM, Wood SF. Non-compliance amongst adolescents with asthma: listening to what they tell us about self-management. Fam Pract 2000; 17: 134-138.
33. Boulet L-P. Perception of the role and potential side effects on inhaled corticosteroids. Chest 1998; 113: 587-592.
34. Clark N, Jones P, Keller S, Vermeire P. Patient factors and compliance with asthma therapy. Respir Med 1999; 93: 856-862.
35. Liljas B, Ståhl E, Pauwels RA. Cost-effectiveness analysis of a dry powder inhaler (Turbuhaler®) versus a pressurised metered dose inhaler in patients with asthma. Pharmacoeconomics 1997; 12 (2 Pt 2): 267-277.
36. Sculpher MJ, Buxton MJ. The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy. Pharmacoeconomics 1993; 4: 345-352.
37. Rutten-van Molken MP, Van Doorslaer EK, Jansen MC, Essen-Zandvliet EE, Rutten FF. Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. Pharmacoeconomics 1993; 4: 257-270.
38. Connett GJ, Lenney W, McConchie SM. The cost effectiveness of budesonide in severe asthmatics aged one to three years. Br J Med Econ 1993; 6: 127-134.
39. Rutten-van Molken MP, Van Doorslaer EK, Jansen MC, Kerstjens HA, Rutten FF. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 975-982.
40. -1 in the management of mild-to-moderate asthma in general practice. Br J Med Econ 1993; 6: 67-74.
41. Pauwels RA, Lofdahl C-G, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
42. Kips JC, O'Connor JB, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996-1001.
43. Juniper EF, Svensson K, O'Byrne PM et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999; 14: 1038-1043.
44. Zetterström O, Buhl R, Mellem H, Perpina M, Hedman J, O'Neill S. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18: 1-7
45. Andersson F, Buhl R, Mellem H, Borg S, Hjelmgren J, Zetterström O. Symbicort® Turbuhaler® is a cost-effective treatment in adult asthmatics. J Allergy Clin Immunol 2001; 107: S245.
46. Ten Thoren C, Petermann F. Reviewing asthma and anxiety. Respir Med 2000; 94: 409-415.
47. Doan T, Patterson R, Greenberger PA. Cough variant asthma: usefulness of a diagnostic-therapeutic trial with prednisone. Ann Allergy 1992; 69: 505-509.
48. Juniper EF. Quality-of-life considerations in the treatment of asthma. Pharmacoeconomics 1995; 8: 123-138.
49. Chapman KR, Walker L, Cluley S, Fabbri L. Improving patient compliance with asthma therapy. Respir Med 2000; 94: 2-9.
50. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-1884.
51. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47: 555-567
52. Schmier JK, Leidy NK. The complexity of treatment adherence in adults with asthma: challenges and opportunities. J Asthma 1998; 35: 455-472.
53. Brown PH, Lenney J, Armstrong S, Ning AC, Crompton GK. Breath-actuated inhalers in chronic asthma: comparison of Diskhaler® and Turbohaler® for delivery of beta-agonists. Eur Respir J 1992; 5: 1143-1145.
54. Crompton GK. Problems patients have using pressurised aerosol inhalers. Eur J Respir Dis 1982; 63 (Suppl 119): 101-104.
55. Schlaeppi M, Edwards K, Fuller RW, Sharma R. Patient perception of the Diskus inhaler: a comparison with the Turbuhaler inhaler. Br J Clin Pract 1996; 50: 14-19.
56. Williams J, Richards KA. Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/Diskus™ inhaler compared with the Turbohaler™ inhaler in paediatric patients. UK Study Group. Br J Clin Pract 1997; 51: 147-153.
57. Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 1999; 58 (Suppl 4): 25-33; Discussion 52.